Erratum to: Visceral obesity and metabolic syndrome: Two faces of the same medal? (Intern Emerg Med, (2010), 5, (111-119), 10.1007/s11739-009-0332-6);Visceral obesity and metabolic syndrome: Two faces of the same medal?

Internal and Emergency Medicine

Volumn 5, Issue 2, 2010, Pages 111-119

  Scaglione, Rosario ^a   Di Chiara, Tiziana ^a   Cariello, Tiziana ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Adipocytokines; Adiponectin; Metabolic syndrome; Visceral obesity

Indexed keywords

EID: 77953361791     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0419-0     Document Type: Erratum

References (50)

1. Avogaro P, Crepaldi G (1965) Essential hyperlipidemia, obesity and diabetes. Diabetologia 1: 137.
2. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
3. Bays H, Abate N, Chandalia M (2005) Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol 1: 39-59.
4. Licata G, Corrao S, Parrinello G, Scaglione R (1996) Obesity and Cardiovascular diseases. Excerpta Med 1: 5-166.
5. Vague J (1947) La differenciation sexuelle, facteur determinant des formes de l'obesite. Press Med 30: 339-340.
6. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW (1999) Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 341: 1097-1105.
7. Kaplan RC, Heckbert SR, Furberg CD, Psaty BM (2002) Predictors of subsequent coronary events, stroke and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 55: 654-664.
8. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M et al (2007) Abdominal obesity: role in the patophysiology of metabolic disease and cardiovascular risk. Am J Med 120: S3-S8.
9. Reaven GM (2005) The metabolic syndrome: requiescat in pace. Clin Chem 51: 931-938.
10. Definition and classification of diabetes mellitus and its complications. Report of a WHO document. WHO/NCD/NCS/99. pp 31-33, 1999.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
12. Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16: 442-443.
13. Grundy SM (2005) Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscl Thromb Vasc Biol 25: 2243-2244.
14. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome: a world-wide definition. A consensus statement of the International Diabetes Federation. Diabet Med 23: 469-480.
15. Strazzullo P, Barbaro A, Siani A, Cappuccio FP, Versiero M, Schiattarella P et al (2008) Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population. Metabolism 57: 355-361.
16. Matsuzawa Y (2006) The metabolic syndrome and adipocytokines. FEBS 580: 2917-2921.
17. Galletti F, Barbato A, Versiero M, Iacone R, Russo O, Barba G et al (2007) Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8 year follow-up study. J Hypert 25: 1671-1677.
18. Yaney GC, Corkey BE (2003) Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 46: 1297-1312.
19. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 111: 1448-14542.
20. Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S et al (1995) Haemostatic function in young subjects with central obesity: relationship with left ventricular function. Metabolism 44: 1417-1421.
21. Licata G, Di Chiara T, Licata A, Triolo G, Argano C, Parrinello G et al (2003) Relationship between circulating E-selectin, DD genotype of angiotensin converting enzyme, and cardiovascular damage in central obese subjects. Metabolism 52: 999-1004.
22. Licata G, Volpe M, Scaglione R, Rubattu S (1994) Salt regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23(Suppl I): 20-24.
23. Scaglione R, Dichiara MA, Indovina A, Lipari R, Ganguzza A, Parrinello G, Capuana G, Merlino G, Licata G (1992) Left ventricular diastolic and systolic function in normotensive obese subjects: influence of degree and duration of obesity. Eur Heart J 13: 738-742.
24. Licata G, Scaglione R, Paterna S, Parrinello G, Indovina A, Dichiara MA, Alaimo G, Merlino G (1992) Left ventricular function response to exercise in normotensive obese subjects: influence of degree and duration of obesity. Int J Cardiol 37: 223-230.
25. Galletti F, Strazzullo P (2007) Involvement of the renin-angiotensin system in obesity: older and newer patways. NMCD 17: 699-674.
26. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A (2008) Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome and hypertension: an integrated view in humans. J Hypert 26: 831-843.
27. Takahashi M, Arita Y, Yamagata K (2000) Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Rel Metab Disord 24: 861-868.
28. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocrine Rev 26: 439-451.
29. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H et al (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42: 231-232.
30. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR et al (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10: 1384-1389.
31. Tarquini R, Lazzeri C, Laffi G, Genuini GF (2007) Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med 2: 165-176.
32. Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271: 10697-10703.
33. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83.
34. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-1935.
35. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al (2001) Secretion and regulation of apM 1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288: 1102-1107.
36. Maeda N, Takanashi M, Funashashi T, Kihara S, Nishizawa H, Kishida K et al (2001) PPAR gamma ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099.
37. Diez JJ, Iglesias P (2003) The role of novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148: 293-300.
38. Shargorodsky M, Boaz M, Goldberg Y, Matas Z, Gavish D, Fux A, Wolfson N (2009) Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis? Int J Obes 33: 553-558.
39. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
40. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscl Thromb Vasc Biol 23: 85-89.
41. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141.
42. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H (2006) Serum concentration of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. JACC 48: 1369-1372.
43. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zetelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92: 571-576.
44. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM et al (2006) Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114: 623-629.
45. Lawlor DA, Dawey Smith G, Ebrahim S, Thompson C, Sattar N (2005) Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90: 5677-5683.
46. Yang WS, Yang YC, Chen CL, Wu IL, Lu JK, Lu FH et al (2007) Adiponectin SNP276 is associated with obesity, the metabolic syndrome, and diabetes in the elderly. Am J Clin Nutr 86: 509-513.
47. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T et al (2002) Low plasma adiponectin concentration do not predict weight gain in humans. Diabetes 51: 2964-2967.
48. Duncan BB, Scmidt ML, Pankow JS, Bang H, Couper D, Ballantyne CN et al (2004) Adiponectin and the development of type 2 diabetes in the atherosclerosis risk in communities study. Diabetes 53: 2473-2478.
49. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al (2002) Synthetic peroxisome proliferators-activated receptor gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25: 376-380.
50. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al (2003) Blockade of the renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 42: 76-81.